These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 9727571)

  • 1. A randomized trial of the effect of ritonavir in maintaining quality of life in advanced HIV disease. Advanced HIV Disease Ritonavir Study Group.
    Cohen C; Revicki DA; Nabulsi A; Sarocco PW; Jiang P
    AIDS; 1998 Aug; 12(12):1495-502. PubMed ID: 9727571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality of life outcomes of combination zalcitabine-zidovudine, saquinavir-zidovudine, and saquinavir-zalcitabine-zidovudine therapy for HIV-infected adults with CD4 cell counts between 50 and 350 per cubic millimeter. PISCES (SV14604) Study Group.
    Revicki DA; Moyle G; Stellbrink HJ; Barker C
    AIDS; 1999 May; 13(7):851-8. PubMed ID: 10357386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group.
    Cameron DW; Heath-Chiozzi M; Danner S; Cohen C; Kravcik S; Maurath C; Sun E; Henry D; Rode R; Potthoff A; Leonard J
    Lancet; 1998 Feb; 351(9102):543-9. PubMed ID: 9492772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality of life in asymptomatic- and symptomatic HIV infected patients in a trial of ritonavir/saquinavir therapy. The Prometheus Study Group.
    Nieuwkerk PT; Gisolf EH; Colebunders R; Wu AW; Danner SA; Sprangers MA
    AIDS; 2000 Jan; 14(2):181-7. PubMed ID: 10708289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nucleoside analogs plus ritonavir in stable antiretroviral therapy-experienced HIV-infected children: a randomized controlled trial. Pediatric AIDS Clinical Trials Group 338 Study Team.
    Nachman SA; Stanley K; Yogev R; Pelton S; Wiznia A; Lee S; Mofenson L; Fiscus S; Rathore M; Jimenez E; Borkowsky W; Pitt J; Smith ME; Wells B; McIntosh K
    JAMA; 2000 Jan; 283(4):492-8. PubMed ID: 10659875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized trial comparing the introduction of ritonavir or indinavir in 1251 nucleoside-experienced patients with advanced HIV infection.
    Floridia M; Tomino C; Bucciardini R; Ricciardulli D; Fragola V; Pirillo MF; Amici R; Giannini G; Galluzzo CM; Andreotti M; Seeber AC; Ammassari A; Cingolani A; Lazzarin A; Scalise G; Cargnel A; Suter F; Milazzo F; Pastore G; Moroni M; Ciammarughi R; Pini R; Carosi G; D'Amato C; Contu L; Concia E; Bonazzi L; Aiuti F; Vigevani G; Vella S;
    AIDS Res Hum Retroviruses; 2000 Nov; 16(17):1809-20. PubMed ID: 11118067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protease inhibitor combination therapy, severity of illness, and quality of life among children with perinatally acquired HIV-1 infection.
    Storm DS; Boland MG; Gortmaker SL; He Y; Skurnick J; Howland L; Oleske JM;
    Pediatrics; 2005 Feb; 115(2):e173-82. PubMed ID: 15629958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ritonavir and saquinavir combination therapy for the treatment of HIV infection.
    Cameron DW; Japour AJ; Xu Y; Hsu A; Mellors J; Farthing C; Cohen C; Poretz D; Markowitz M; Follansbee S; Angel JB; McMahon D; Ho D; Devanarayan V; Rode R; Salgo M; Kempf DJ; Granneman R; Leonard JM; Sun E
    AIDS; 1999 Feb; 13(2):213-24. PubMed ID: 10202827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health-related quality of life in HIV patients switching to twice-daily indinavir/ritonavir regimen or continuing with three-times-daily indinavir-based therapy.
    Badía X; Podzamczer D; Moral I; Roset M; Arnaiz JA; Loncà M; Casiró A; Rosón B; Gatell JM;
    Antivir Ther; 2004 Dec; 9(6):979-85. PubMed ID: 15651756
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurodevelopmental/neuroradiologic recovery of a child infected with HIV after treatment with combination antiretroviral therapy using the HIV-specific protease inhibitor ritonavir.
    Tepper VJ; Farley JJ; Rothman MI; Houck DL; Davis KF; Collins-Jones TL; Wachtel RC
    Pediatrics; 1998 Mar; 101(3):E7. PubMed ID: 9493492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality of life outcomes of saquinavir, zalcitabine and combination saquinavir plus zalcitabine therapy for adults with advanced HIV infection with CD4 counts between 50 and 300 cells/mm3.
    Revicki DA; Swartz C; Wu AW; Haubrich R; Collier AC
    Antivir Ther; 1999; 4(1):35-44. PubMed ID: 10682127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study.
    Boyd MA; Amin J; Mallon PW; Kumarasamy N; Lombaard J; Wood R; Chetchotisakd P; Phanuphak P; Mohapi L; Azwa I; Belloso WH; Molina JM; Hoy J; Moore CL; Emery S; Cooper DA;
    Lancet HIV; 2017 Jan; 4(1):e13-e20. PubMed ID: 27815068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High quality of life, treatment tolerability, safety and efficacy in HIV patients switching from triple therapy to lopinavir/ritonavir monotherapy: A randomized clinical trial.
    Pasquau J; Hidalgo-Tenorio C; Montes ML; Romero-Palacios A; Vergas J; Sanjoaquín I; Hernández-Quero J; Aguirrebengoa K; Orihuela F; Imaz A; Ríos-Villegas MJ; Flores J; Fariñas MC; Vázquez P; Galindo MJ; García-Mercé I; Lozano F; de Los Santos I; de Jesus SE; García-Vallecillos C;
    PLoS One; 2018; 13(4):e0195068. PubMed ID: 29649309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults.
    Lalezari JP; DeJesus E; Northfelt DW; Richmond G; Wolfe P; Haubrich R; Henry D; Powderly W; Becker S; Thompson M; Valentine F; Wright D; Carlson M; Riddler S; Haas FF; DeMasi R; Sista PR; Salgo M; Delehanty J
    Antivir Ther; 2003 Aug; 8(4):279-87. PubMed ID: 14518696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.
    Walmsley S; Bernstein B; King M; Arribas J; Beall G; Ruane P; Johnson M; Johnson D; Lalonde R; Japour A; Brun S; Sun E;
    N Engl J Med; 2002 Jun; 346(26):2039-46. PubMed ID: 12087139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of lopinavir/ritonavir monotherapy on quality of life and self-reported symptoms among antiretroviral-naive patients: results of the MONARK trial.
    Spire B; Marcellin F; Cohen-Codar I; Flandre P; Boue F; Dellamonica P; Raffi F; Norton M; Van Philippe N; Delfraissy JF
    Antivir Ther; 2008; 13(4):591-9. PubMed ID: 18672538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.
    Smith KY; Patel P; Fine D; Bellos N; Sloan L; Lackey P; Kumar PN; Sutherland-Phillips DH; Vavro C; Yau L; Wannamaker P; Shaefer MS;
    AIDS; 2009 Jul; 23(12):1547-56. PubMed ID: 19542866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials.
    Eron JJ; Young B; Cooper DA; Youle M; Dejesus E; Andrade-Villanueva J; Workman C; Zajdenverg R; Fätkenheuer G; Berger DS; Kumar PN; Rodgers AJ; Shaughnessy MA; Walker ML; Barnard RJ; Miller MD; Dinubile MJ; Nguyen BY; Leavitt R; Xu X; Sklar P;
    Lancet; 2010 Jan; 375(9712):396-407. PubMed ID: 20074791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality of life and treatment satisfaction after the addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens in treatment-experienced patients with HIV infection.
    Chatterton ML; Scott-Lennox J; Wu AW; Scott J
    Pharmacoeconomics; 1999; 15 Suppl 1():67-74. PubMed ID: 10537443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression.
    Swindells S; DiRienzo AG; Wilkin T; Fletcher CV; Margolis DM; Thal GD; Godfrey C; Bastow B; Ray MG; Wang H; Coombs RW; McKinnon J; Mellors JW;
    JAMA; 2006 Aug; 296(7):806-14. PubMed ID: 16905786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.